Results 141 to 150 of about 4,754 (217)

Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial. [PDF]

PLoS Negl Trop Dis, 2022
Javadi A, Khamesipour A, Ghoorchi M, Bahrami M, Khatami A, Sharifi I, Eskandari SE, Fekri A, Aflatoonian MR, Firooz A.   +9 more
europepmc   +1 more source

Cutaneous Leishmaniasis in Bam: A Comparative Evaluation of Pre- and Post- Earthquake Years (1999-2008) [PDF]

Background: The recent devastating earthquake of December 26 in Bam, 2003 created various risk factors; caused a sharp increase in incidence of anthroponotic cutaneous leishmaniasis (ACL) cases and reached to an epidemic proportion.
Aflatoonian, MR, Fekri, AR, Gooya, MM, Hakimi Parizi, M, Nakhaei, N, Safizadeh, H, Sharifi, I, Shirzadi, MR   +7 more
core  

Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate. [PDF]

Bioanalysis, 2021
Garay-Baquero DJ, Rebellón-Sánchez DE, Prieto MD, Giraldo-Parra L, Navas A, Atkinson S, McDougall S, Gómez MA.   +7 more
europepmc   +1 more source

Therapeutic Potential of Green Synthesized Copper Nanoparticles Alone or Combined with Meglumine Antimoniate (Glucantime^®) in Cutaneous Leishmaniasis. [PDF]

Nanomaterials (Basel), 2021
Albalawi AE, Abdel-Shafy S, Khudair Khalaf A, Alanazi AD, Baharvand P, Ebrahimi K, Mahmoudvand H.   +6 more
europepmc   +1 more source

An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil. [PDF]

PLoS Negl Trop Dis, 2021
Oliveira-Ribeiro C, Pimentel MIF, Oliveira LFA, Vasconcellos ÉCFE, Conceição-Silva F, Schubach AO, Fagundes A, de Mello CX, Mouta-Confort E, Miranda LFC, Valete-Rosalino CM, Martins ACDC, Oliveira RVC, Quintella LP, Lyra MR.   +14 more
europepmc   +1 more source

Response and therapeutic failure to meglumine antimoniate, the first-line drug for cutaneous leishmaniasis infections in Colombian soldiers. [PDF]

Parasitol Res
Pavia PX, Patiño LH, Méndez C, Romero Y, Duque MC, Cruz C, Ramírez JD.   +6 more
europepmc   +1 more source

Topical Meglumine Antimoniate Gel for Cutaneous Leishmaniasis: Formulation, Evaluation, and In Silico Insights. [PDF]

Gels
Sosa L, Espinoza LC, Pujol A, Correa-Basurto J, Méndez-Luna D, Sarango-Granda P, Berenguer D, Riera C, Clares-Naveros B, Calpena AC, Prohens R, Silva-Abreu M.   +11 more
europepmc   +1 more source

Correction: Successful treatment of meglumine antimoniate in patient with cutaneous leishmaniasis with end-stage renal failure undergoing hemodialysis: a case report. [PDF]

J Med Case Rep
Arab H, Alsaffaf Y, Aldolly A, Dukhan A, Douri T.   +4 more
europepmc   +1 more source

Efficacy of meglumine antimoniate treatment on boxer <i>Leishmania infantum</i> skin lesions: case report. [PDF]

Front Vet Sci
Carresi C, Ferrucci CF, Mangano C, Coppoletta AR, Cardamone A, Musolino V, Gliozzi M, Mollace V, Britti D.   +8 more
europepmc   +1 more source

Ozonated Sunflower Oil Stimulates the Local Antioxidant System and Helps Meglumine Antimoniate to Ameliorate Cutaneous Leishmaniasis Lesions. [PDF]

ACS Omega
Cabral IL, Lima LBS, Três DP, Fabrini CD, da Silva GC, Ferreira CZP, Silva FC, Amorim JPA, Ayala TS, Menolli RA.   +9 more
europepmc   +1 more source